More than 1.3 million Americans suffer from rheumatoid arthritis, which is the most common forms of inflammatory arthritis. New therapies and advances in genetics, proteomics, genomics, pharmacology and have made great strides in recent years, however, the cause of and cure are done RA are currently unknown, and without special treatment, eroded bones and joints deformities develop.
The positive recommendation from the labeling extension for TEMODAL is largely based on efficacy and safety data from a landmark Phase III trial of the European Organization for Research and Treatment of Cancer and the National Cancer Institute of Canada were performed. These data were in 10th Published in March 2005 issue of the New England Journal of Medicine. In this multicenter study with 573 patients with newly diagnosed GBM patients, a significant improvement in overall survival in patients Temodal in combination Temodal in combination with radiation therapy compared with those treated with radiotherapy alone has been treated. Continue reading